138 related articles for article (PubMed ID: 32643451)
1. The relationship between HbA1c reduction and healthcare costs among patients with type 2 diabetes: evidence from a U.S. claims database.
Lage MJ; Boye KS
Curr Med Res Opin; 2020 Sep; 36(9):1441-1447. PubMed ID: 32643451
[TBL] [Abstract][Full Text] [Related]
2. Clinical and economic outcomes among injection-naïve patients with type 2 diabetes initiating dulaglutide compared with basal insulin in a US real-world setting: the DISPEL Study.
Mody R; Huang Q; Yu M; Patel H; Zhang X; Wang L; Grabner M
BMJ Open Diabetes Res Care; 2019; 7(1):e000884. PubMed ID: 31875137
[TBL] [Abstract][Full Text] [Related]
3. Relationship of glycemic control to total diabetes-related costs for managed care health plan members with type 2 diabetes.
Shetty S; Secnik K; Oglesby AK
J Manag Care Pharm; 2005 Sep; 11(7):559-64. PubMed ID: 16137213
[TBL] [Abstract][Full Text] [Related]
4. Impact of Reducing Glycated Hemoglobin on Healthcare Costs Among a Population with Uncontrolled Diabetes.
Bansal M; Shah M; Reilly B; Willman S; Gill M; Kaufman FR
Appl Health Econ Health Policy; 2018 Oct; 16(5):675-684. PubMed ID: 29936685
[TBL] [Abstract][Full Text] [Related]
5. Impact of delaying treatment intensification with a glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes uncontrolled on basal insulin: A longitudinal study of a US administrative claims database.
Tong L; Pan C; Wang H; Bertolini M; Lew E; Meneghini LF
Diabetes Obes Metab; 2018 Apr; 20(4):831-839. PubMed ID: 29119712
[TBL] [Abstract][Full Text] [Related]
6. Real-world persistence, adherence, health care resource utilization, and costs in people with type 2 diabetes switching from a first-generation basal insulin to a second-generation (insulin glargine 300 U/mL) vs an alternative first-generation basal insulin.
Wright EE; Malone DC; Trujillo JM; Gill J; Huse S; Li X; Zhou FL; Preblick R; Reid T
J Manag Care Spec Pharm; 2022 Jun; 28(6):592-603. PubMed ID: 35352995
[No Abstract] [Full Text] [Related]
7. The association between the severity of chronic kidney disease and medical costs among patients with type 2 diabetes.
Lage MJ; Boye KS; Bae JP; Wu J; Mody R; Botros FT
J Med Econ; 2019 May; 22(5):447-454. PubMed ID: 30736708
[TBL] [Abstract][Full Text] [Related]
8. Real-world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 units/mL vs other basal insulins in patients with type 2 diabetes using basal insulin.
Zhou FL; Ye F; Berhanu P; Gupta VE; Gupta RA; Sung J; Westerbacka J; Bailey TS; Blonde L
Diabetes Obes Metab; 2018 May; 20(5):1293-1297. PubMed ID: 29272064
[TBL] [Abstract][Full Text] [Related]
9. The Association Between HbA1c and 1-Year Diabetes-Related Medical Costs: A Retrospective Claims Database Analysis.
Boye KS; Lage MJ; Thieu VT
Diabetes Ther; 2022 Feb; 13(2):367-377. PubMed ID: 35129822
[TBL] [Abstract][Full Text] [Related]
10. HBA1C CONTROL AND COST-EFFECTIVENESS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INITIATED ON CANAGLIFLOZIN OR A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST IN A REAL-WORLD SETTING.
Wysham CH; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Pfeifer M; Lefebvre P
Endocr Pract; 2018 Mar; 24(3):273-287. PubMed ID: 29547044
[TBL] [Abstract][Full Text] [Related]
11. Hemoglobin A1c outcomes and health care resource use in type 2 diabetes mellitus patients treated with combination oral antidiabetic drugs through step therapy and loose-dose and fixed-dose combinations.
Williams SA; Buysman EK; Hulbert EM; Bergeson JG; Zhang B; Graham J
Manag Care; 2012 Jul; 21(7):40-8. PubMed ID: 22876522
[TBL] [Abstract][Full Text] [Related]
12. Effects of telemonitoring on glycaemic control and healthcare costs in type 2 diabetes: A randomised controlled trial.
Warren R; Carlisle K; Mihala G; Scuffham PA
J Telemed Telecare; 2018 Oct; 24(9):586-595. PubMed ID: 28814128
[TBL] [Abstract][Full Text] [Related]
13. Canadian Potential Healthcare and Societal Cost Savings from Consumption of Pulses: A Cost-Of-Illness Analysis.
Abdullah MMH; Marinangeli CPF; Jones PJH; Carlberg JG
Nutrients; 2017 Jul; 9(7):. PubMed ID: 28737688
[TBL] [Abstract][Full Text] [Related]
14. A comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with type 2 diabetes.
Borah BJ; Darkow T; Bouchard J; Aagren M; Forma F; Alemayehu B
Clin Ther; 2009 Mar; 31(3):623-31. PubMed ID: 19393853
[TBL] [Abstract][Full Text] [Related]
15. Healthcare costs among adults with type 2 diabetes initiating saxagliptin or linagliptin: a US-based claims analysis.
Kong AM; Farahbakhshian S; Pendergraft T; Brouillette MA; Mukherjee B; Smith DM; Sheehan JJ
Curr Med Res Opin; 2017 Oct; 33(10):1869-1877. PubMed ID: 28613952
[TBL] [Abstract][Full Text] [Related]
16. Impact of adherence to antidepressants on healthcare outcomes and costs among patients with type 2 diabetes and comorbid major depressive disorder.
Vega C; Becker RV; Mucha L; Lorenz BH; Eaddy MT; Ogbonnaya AO
Curr Med Res Opin; 2017 Oct; 33(10):1879-1889. PubMed ID: 28644095
[TBL] [Abstract][Full Text] [Related]
17. Distribution and drivers of costs in type 2 diabetes mellitus treated with oral hypoglycemic agents: a retrospective claims data analysis.
Bron M; Guerin A; Latremouille-Viau D; Ionescu-Ittu R; Viswanathan P; Lopez C; Wu EQ
J Med Econ; 2014 Sep; 17(9):646-57. PubMed ID: 24959693
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland.
Brändle M; Azoulay M; Greiner RA
Int J Clin Pharmacol Ther; 2007 Apr; 45(4):203-20. PubMed ID: 17474539
[TBL] [Abstract][Full Text] [Related]
19. An economic evaluation of colesevelam when added to metformin-, insulin- or sulfonylurea-based therapies in patients with uncontrolled type 2 diabetes mellitus.
Simons WR; Hagan MA
Pharmacoeconomics; 2010; 28(9):765-80. PubMed ID: 20799756
[TBL] [Abstract][Full Text] [Related]
20. Impact of Perioperative HbA1c on Reimbursements in Diabetes Mellitus Patients Undergoing Total Hip Arthroplasty: A Nationwide Analysis.
Kurowicki J; Rosas S; Khlopas A; Newman JM; Law TY; Roche MW; Higuera CA; Mont MA
J Arthroplasty; 2018 Jul; 33(7):2038-2042. PubMed ID: 29891083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
